Research programme: neuroprotective therapeutics - Neuropathix
Alternative Names: Sulphamide containing neuroprotective compounds - NeuropathixLatest Information Update: 30 Dec 2020
At a glance
- Originator Advanced Neural Dynamics; Fox Chase Chemical Diversity Center
- Developer Advanced Neural Dynamics; Fox Chase Chemical Diversity Center; Neuropathix
- Class Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Epilepsy; Neuropathic pain
Most Recent Events
- 21 Dec 2020 The neuroprotective therapeutics programme has been validated under a SBIR NIH study grant
- 21 Dec 2020 Early research in Neuropathic pain in USA
- 18 Dec 2020 Neuropathix acquires neuroprotective and anticonvulsant IP estate from the Fox Chase Chemical Diversity Center and Advanced Neural Dynamics